Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Evelyne T. Edwards"'
Autor:
Evelyne T. Edwards, Sharon K. Gershon, Jeffrey Siegel, M. Miles Braun, Jong-Hoon Lee, Robert P. Wise, Nancy R. Slifman, John N. Udall, S. Lori Brown, William D. Schwieterman
Publikováno v:
Arthritis & Rheumatism. 46:2565-2570
Objective Two tumor necrosis factor α (TNFα) antagonists were recently licensed in the US. Infliximab was licensed in 1998 for the treatment of Crohn's disease (CD), and since 1999, it has been licensed in combination with methotrexate for treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eccc21f0dc82a6053606d360156431e3
https://doi.org/10.1002/art.10583
https://doi.org/10.1002/art.10583
Autor:
Evelyne T. Edwards, Jeffrey Siegel, Patrick J. Oliverio, Glenn D. Sandberg, John R. Richert, Thomas R. Cupps, Niveditha Mohan, Heidi Crayton
Publikováno v:
Arthritis & Rheumatism. 44:2862-2869
Objective. To review the occurrence of neurologic events suggestive of demyelination during anti-tumor necrosis factor a (anti-TNFa) therapy for inflammatory arthritides. Methods. The Adverse Events Reporting System of the Food and Drug Administratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f542fc82462edc5e03cae3f7f3947179
https://doi.org/10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co
https://doi.org/10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co
Autor:
Niveditha, Mohan, Evelyne T, Edwards, Thomas R, Cupps, Nancy, Slifman, Jong-Hoon, Lee, Jeffrey N, Siegel, M Miles, Braun
Publikováno v:
The Journal of rheumatology. 31(10)
To describe the clinical features of leukocytoclastic vasculitis (LCV) associated with the use of tumor necrosis factor-alpha (TNF-alpha) blockers.The Adverse Events Reporting System (AERS) of the US Food and Drug Administration (FDA) was queried for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ad11f0e643fb9699b96a12138566b786
https://pubmed.ncbi.nlm.nih.gov/16206372
https://pubmed.ncbi.nlm.nih.gov/16206372
Publikováno v:
Arthritis and rheumatism. 48(2)
Objective Tumor necrosis factor α (TNFα) has been implicated in the pathogenesis of certain inflammatory diseases. Two TNFα-neutralizing agents are licensed in the US. Infliximab is licensed for the treatment of Crohn's disease (CD) and, when used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baf0af03773bd287edae0dfbfcace481
https://pubmed.ncbi.nlm.nih.gov/12571839
https://pubmed.ncbi.nlm.nih.gov/12571839
Publikováno v:
Arthritis and rheumatism. 46(12)
Objective Etanercept and infliximab are tumor necrosis factor (TNF) antagonists that have been recently approved for the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). This study was undertaken to investigate the occurrence of lymph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a997ff5706ee82b48f26d32786c0fd8b
https://pubmed.ncbi.nlm.nih.gov/12905496
https://pubmed.ncbi.nlm.nih.gov/12905496
Publikováno v:
The Lancet. 360:646
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f97aa719f8ef02b5f985abd168f33a2e
https://doi.org/10.1016/s0140-6736(02)09800-8
https://doi.org/10.1016/s0140-6736(02)09800-8